AVTX_OUT_1 [2025-04-02 08:19:29 -0400] 2714 Bytes | 771 tokens | Cum: 771 tkns (9.64% of 8k)
==========================================================================

We need a winner today and it's already 8:19:28 AM on Wed Apr 02, 2025 -0400 ... So let's find out if Avalo Therapeutics (AVTX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 7.9 up from 6.85. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Avalo Therapeutics (AVTX)
IPO: 2015-11-13 (9 Years Ago)
Market Cap: $73,102,748
Shares Outstanding: 10,670,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Here's the first list of news for Avalo Therapeutics:

C1 - Mar-26-25 07:00AM - Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
C2 - Mar-20-25 07:00AM - Avalo Reports 2024 Financial Results and Recent Business Updates
C3 - Feb-24-25 07:00AM - Avalo Therapeutics to Participate in Upcoming Investor Conferences
C4 - Feb-04-25 08:00AM - Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
C5 - Jan-02-25 07:00AM - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
C6 - Dec-20-24 06:50AM - Avalo Therapeutics initiated with a Buy at BTIG
C7 - Nov-12-24 07:00AM - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
C8 - Nov-11-24 07:00AM - Avalo Therapeutics to Present at Upcoming Investor Conferences

Prior AI Reports for AVTX:
1. 2025-03-25 – Score: 55 – Target: 10.0000 – Highs: 9.6999 / 8.9900 / 9.00
avalo-therapeutics-high-trading-volume-amid-declining-sales

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Avalo Therapeutics (AVTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

AVTX_OUT_3 [2025-04-02 08:19:32 -0400] 1104 Bytes | 327 tokens | Cum: 1100 tkns (13.75% of 8k)
==========================================================================

Showing C2 (chunk 1 of 8): C2:
**Avalo Reports 2024 Financial Results and Recent Business Updates**
Date: Mar-20-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046094/0/en/Avalo-Reports-2024-Financial-Results-and-Recent-Business-Updates.html

March 20, 2025 07:00 ET| Source:Avalo TherapeuticsAvalo Therapeutics

WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024.

“2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AVTX_OUT_5 [2025-04-02 08:19:33 -0400] 915 Bytes | 281 tokens | Cum: 1460 tkns (18.25% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-28T05:05:18Z - Avalo Therapeutics (AVTX) to Release Earnings on Friday...
A2 - 2025-03-26T14:34:10Z - Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts...
A3 - 2025-03-26T12:34:54Z - Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel Nicolaus...
A4 - 2025-03-26T12:34:48Z - Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Jefferies Financial Group...
A5 - 2025-03-26T11:11:46Z - Avalo Therapeutics names Michael Heffernan as chair (AVTX:NASDAQ)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AVTX_OUT_7 [2025-04-02 08:19:34 -0400] 1098 Bytes | 324 tokens | Cum: 1786 tkns (22.32% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Avalo Therapeutics (AVTX) to Release Earnings on Friday**Date: 2025-03-28Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/avalo-therapeutics-avtx-to-release-earnings-on-friday-2025-03-28/Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of $0.58 per share for the quarter.

NASDAQ:AVTX opened at $8.73 on Friday. Avalo Therapeutics has a 1 year low of $5.99 and a 1 year high of $34.46. The stock's 50 day simple moving average is $7.59 and its two-hundred day simple moving average is $9.13.

AVTX has been the subject of several research reports. HC Wainwright reiterated a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jef

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AVTX_OUT_9 [2025-04-02 08:19:35 -0400] 924 Bytes | 279 tokens | Cum: 2067 tkns (25.84% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-02T12:00:00Z - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
B2 - 2024-11-12T12:00:00Z - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
B3 - 2024-11-11T12:00:00Z - Avalo Therapeutics to Present at Upcoming Investor Conferences
B4 - 2024-07-16T11:05:45Z - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire
B5 - 2024-06-24T20:01:00Z - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
B6 - 2024-06-17T11:30:00Z - Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AVTX_OUT_11 [2025-04-02 08:19:38 -0400] 789 Bytes | 200 tokens | Cum: 2269 tkns (28.36% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/02/3003444/0/en/Avalo-Therapeutics-Appoints-Jennifer-Riley-as-Chief-Strategy-Officer.htmlAvalo Therapeutics, a clinical-stage biotechnology company, has appointed Jennifer Riley as its new Chief Strategy Officer. Riley brings extensive experience in the biotechnology and pharmaceutical industries, and will oversee corporate strategy, commercial and product pipeline planning to drive growth and innovation at Avalo.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AVTX_OUT_13 [2025-04-02 08:19:38 -0400] 238 Bytes | 59 tokens | Cum: 2386 tkns (29.83% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AVTX_OUT_15 [2025-04-02 08:19:49 -0400] 5991 Bytes | 1787 tokens | Cum: 4176 tkns (52.20% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 28,465 | Perf Month: 2.24% | Option/Short: No / Yes | Sales Y/Y TTM: -77.09% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 76.36K | Perf Quarter: -17.77% | Short Float: 1.12% | ROE: -50.06% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.36 | Index: - | Short Ratio: 1.26 | ROI: -108.44% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 41.31 | Market Cap: 73.10M | Short Interest: 0.10M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.94 | Shs Outstand: 10.47M | Beta: 0.84 | EPS Surprise: -274.33% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -11.99% | Shs Float: 8.57M | Sales Q/Q: -66.37% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -10.32% | Inst Own: 56.98% | Sales past 5Y: 9.56% | Earnings: Mar 20 BMO |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -29.52% | Insider Own: 19.68% | Employees: 23 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -19.79% | Insider Trans: 0.05% | Debt/Eq: 0.02 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Chan Mitchell (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by NEIL GARRY ARTHUR (Chief Executive Officer) on 2025-03-28
- Common Stock: 64867 shares at $N/A (D)
- Common Stock: 17787 shares at $8.46 (D)
- Restricted Stock Units: 64867 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Sullivan Christopher Ryan (Chief Financial Officer) on 2025-03-28
- Common Stock: 24200 shares at $N/A (D)
- Common Stock: 7285 shares at $8.46 (D)
- Restricted Stock Units: 24200 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Almenoff June Sherie (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by KAPLAN GILLA (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Truex Samantha (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Goldman Jonathan (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by KANTOFF AARON (Unknown Title) on 2025-03-28
- Common Stock: 3167 shares at $N/A (D)
- Restricted Stock Units: 3167 shares at $0 (D)

No transactions recorded.

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Heffernan Michael Thomas (Unknown Title) on 2025-03-25
- Stock Option (Right to Buy): 50000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 441000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -35129000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6.85
Average Volume: 103199.05
30-Day High: 8.73
30-Day Low: 6.7

[Detailed Financials: TTM 2024]
- Total Assets: $150,732,000.0
- Total Liabilities: $17,700,000.0
- Total Equity: $133,032,000.0
- Current Assets: $138,890,000.0
- Current Liabilities: $6,960,000.0

[Income Statement: TTM 2024]
- Revenue: $441,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.94

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $127,149,000.0

[Detailed Financials: FY 2024]
- Total Assets: $150,732,000.0
- Total Liabilities: $17,700,000.0
- Total Equity: $133,032,000.0
- Current Assets: $138,890,000.0
- Current Liabilities: $6,960,000.0

[Income Statement: FY 2024]
- Revenue: $441,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.94

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $127,149,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

AVTX_OUT_17 [2025-04-02 08:19:54 -0400] 676 Bytes | 167 tokens | Cum: 4604 tkns (57.55% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

AVTX_IN_19 [2025-04-02 08:19:54 -0400] 126 Bytes | 29 tokens | Cum: 4725 tkns (59.06% of 8k)
==========================================================================

====================================
[2025-04-02 08:19:54] # Analysis Completed
Elapsed Time: 26.23 seconds